These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6218574)

  • 1. Moxalactam therapy for bacterial pneumonia.
    Perlino CA
    Rev Infect Dis; 1982; 4 Suppl():S617-22. PubMed ID: 6218574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxalactam therapy for bacterial infections.
    Winston DJ; Busuttil RW; Kurtz TO; Young LS
    Arch Intern Med; 1981 Nov; 141(12):1607-12. PubMed ID: 6458253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxalactam in the treatment of pediatric infections.
    Yogev R; Schreiber M; Gardner S; Shulman ST
    Am J Dis Child; 1982 Sep; 136(9):836-9. PubMed ID: 6214182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moxalactam for treatment of nosocomial infections.
    Winston DJ; Kurtz TO; Young LS; Busuttil RW
    Rev Infect Dis; 1982; 4 Suppl():S650-S655. PubMed ID: 6218578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of moxalactam: evidence of decreased efficacy in gram-positive aerobic infections.
    Salzer W; Pegram PS; McCall CE
    Antimicrob Agents Chemother; 1983 Apr; 23(4):565-70. PubMed ID: 6222696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of lower respiratory tract infections with moxalactam.
    Lentino JR; Rytel MW; Moore E
    Antimicrob Agents Chemother; 1981 May; 19(5):801-6. PubMed ID: 6457557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxalactam therapy of bacterial meningitis in adults.
    Uwaydah M; Tannir N; Kantarjian H; Osseiran M; Bal'a F
    Antimicrob Agents Chemother; 1983 Feb; 23(2):289-92. PubMed ID: 6220673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of moxalactam.
    Livingston WK; Elliott AM; Dismukes WE; Avent CK; Cobbs CG
    Antimicrob Agents Chemother; 1981 Jul; 20(1):88-97. PubMed ID: 6456688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.
    Murphy TF; Barza M
    Antimicrob Agents Chemother; 1982 Apr; 21(4):568-74. PubMed ID: 6211137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxalactam therapy for gram-negative bacillary meningitis.
    Rahal JJ
    Rev Infect Dis; 1982; 4 Suppl():S606-9. PubMed ID: 6218572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The French experience with moxalactam in pneumology].
    Leng B; Imbert Y; Coomans D
    Sem Hop; 1983 Jun; 59(26):1977-80. PubMed ID: 6310790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of intraabdominal infection with moxalactam.
    Murphy TF; Barza M
    Rev Infect Dis; 1982; 4 Suppl():S670-5. PubMed ID: 6218581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of moxalactam in the treatment of respiratory tract infections, hepatobiliary infections, and septicemia.
    Saito A
    Rev Infect Dis; 1982; 4 Suppl():S623-8. PubMed ID: 6218575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of moxalactam therapy.
    Venezio FR; Westenfelder GO; Cook FV; Williams JE; Carruthers M; Reisberg BE; Emmerman J; Phair JP
    J Antimicrob Chemother; 1982 Nov; 10(5):435-43. PubMed ID: 6217184
    [No Abstract]   [Full Text] [Related]  

  • 15. Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections.
    Oblinger MJ; Bowers JT; Sande MA; Mandell GL
    Rev Infect Dis; 1982; 4 Suppl():S639-49. PubMed ID: 6218577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of moxalactam with the combination of clindamycin and an aminoglycoside in the treatment of common surgical infections.
    Rambo WM; Del Bene VE; Burkey LG; Collins CD; Richmond DK
    Rev Infect Dis; 1982; 4 Suppl():S683-7. PubMed ID: 6218583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.
    Platt R; Ehrlich SL; Afarian J; O'Brien TF; Pennington JE; Kass EH
    Antimicrob Agents Chemother; 1981 Sep; 20(3):351-5. PubMed ID: 6458233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
    Fitzpatrick BJ; Standiford HC
    Pharmacotherapy; 1982; 2(4):197-212. PubMed ID: 6221237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.
    Preheim LC; Penn RG; Sanders CC; Goering RV; Giger DK
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1037-41. PubMed ID: 6218778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxalactam treatment of serious infections primarily due to Haemophilus influenzae type b in children.
    Kaplan SL; Mason EO; Kvernland SJ; Loiselle EM; Feigin RD
    Pediatrics; 1983 Feb; 71(2):187-91. PubMed ID: 6218472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.